secwatch.observer — SEC 8-K summary
======================================

Issuer:     enVVeno Medical Corp (NVNO)
CIK:        0001661053
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001493152-25-012181
Event type: regulatory
Sentiment:  negative
Materiality: 0.95
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enVVeno receives FDA not-approvable letter for VenoValve PMA
------------------------------------------------------------

- FDA issued not-approvable letter for VenoValve PMA, citing insufficient benefit-risk profile.
- FDA raised concerns about bias without hemodynamic measurement and safety from open surgical procedure.
- Company reviewing options including resubmission or appeal; continues to work with FDA.
- VenoValve is lead product for severe deep chronic venous insufficiency; no approved effective treatments currently.
- Company also developing non-surgical enVVe valve; expects to apply learnings for its IDE application.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661053/000149315225012181/0001493152-25-012181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661053/000149315225012181/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer